Tarilian Laser Technologies (TLT) Named as Finalist in The 10th IOT/WT Innovation World Cup®

Tarilian Laser Technologies (TLT) Named as Finalist in The  10th IOT/WT Innovation World Cup®


London, 7th December 2018.

Tarilian Laser Technologies (TLT) are pleased to announce that TLT has been named as a Finalist in The  10th IOT/WT Innovation World Cup® in the Top Innovators Healthcare Category.

According to the World Cup Committee, The  10th IOT/WT Innovation World Cup® was an extraordinary edition, with almost 500 ground-breaking submissions from all over the world registering to the leading innovation competition in the Internet of Things. TLT and ViCardio will showcase their innovative solutions at the official pitch and award ceremony to be held in Munich on February 5th 2019 at the 33rd WT|Wearable Technologies EUROPE 2019.

Commenting on the Nomination, Dr Sandeep Shah, CEO of Tarilian Laser Technologies and ViCardio Limited stated “ TLT is proud to have been nominated for this prestigious Global Award. This demonstrates the recognition around the world of the power of our unique digital medical technology and it’s ability to change healthcare. We look forward to this exciting global  event in Munich in 2019.”

Full details of the awards and finalists can be found at: https://www.innovationworldcup.com/top-22-iot-innovators-of-the-year-we-will-talk-about-in-2019/

About Tarilian Laser Technologies Limited

Tarilian Laser Technologies Limited (TLT) is a Medtech Company based in Welwyn Garden City, Hertfordshire, UK (Head Office and Labs), as well as having its Vicardio® Commercial office in Leeds, UK and also its US operations office in Minneapolis, Minnesota, USA.  TLT is also opening a new regulatory office in Singapore. Our main clinical centre is The Barts Heart Centre in London, Europe’s largest cardiovascular research centre.

Please see: www.tarilian.co.uk to directly access the 30-minute Bloomberg World-Wide Business Interview that summarises TLT and Vicardio®.

TLT is an advanced Medtech SME and is 13485(2016) registered with solid competencies in medical engineering, research & development, clinical trials, regulatory affairs and commercialisation. TLT has developed a novel optical platform based on its internal proprietary patented opto-electronic micro-sensor for full haemodynamic profiling including an ability to generate beat to beat blood pressure, compliance data, cardiac output and regional blood flow and blood pressure.  A unique aspect of the TLT Sapphire sensor is that no energy enters the body at all – hence it is truly NON-invasive and also does not require any compression/cuff and or require any calibration in any manner. You simply apply the sensor on the body and it works instantly delivering continuous beat to beat haemodynamic data. The technology has already won many awards and TLT has continued with a number of additional break-throughs in sensor development- and now is planning a series of product launches from Early 2019, to begin the introduction of the technology into a number of international Medtech and consumer wearable markets.


About ViCardio Limited

ViCardio Limited was set up as a commercialisation company by Tarilian Laser Technologies Limited (TLT) in early 2018 with the mission to improve the diagnosis, monitoring and control of blood pressure in the community. The ViCardio® product is TLT’s first wearable blood pressure monitor, powered by TLT’s proprietary optical-electronic micro-motion sensor that allows blood pressure to be measured with each beat of the heart using a simple and elegant wrist-based wearable. For more information, visit www.vicardio.com and www.tarilian.co.uk

The ViCardio® device is currently being submitted for European CE mark approval and FDA Clearance. The first thousand devices are anticipated to be available for online purchase in approximately early 2019, following CE marking clearance. 


For more information please contact:

Dr Sandeep Shah, CEO of TLT and ViCardio:


Office: +44 (0) 1707 332 883


Comments are closed.